Ashraf Amanullah

Dr. Amanullah is responsible for the late-stage activities required for the commercialization of their programs. He brings more than 20 years of experience in process development, technical operations, cGMP clinical manufacturing, commercialization, and life cycle management of antibody therapeutics, vaccines, gene therapy, cell-based therapeutics, and recombinant proteins.

Before joining Inhibrx, Dr. Amanullah held executive and senior-level positions with aTyr Pharma, Gilead Sciences, Genentech, and Merck. He’s the author of 55 peer-reviewed publications, and his work has been presented at over 120 conferences. He’s on the editorial board of the Biotechnology & Bioengineering and mAb journals. Dr. Amanullah received his Ph.D. in Chemical Engineering from the University of Birmingham (UK) and conducted postdoctoral studies with the University of Birmingham, Novo Nordisk, Merck Sharpe & Dohme, and University College London.